Advertisement


Joshua Armenia, PhD, on Prostate Cancer: Recent Discoveries

2017 Genitourinary Cancers Symposium

Advertisement

Joshua Armenia, PhD, of Memorial Sloan Kettering Cancer Center, discusses new information that is changing the understanding of prostate cancer, including the identification of a new subclass, which represents 21% of cases, and the discovery of recurrently mutated cancer pathways not previously implicated in prostate cancer (Abstract 131).



Related Videos

Kidney Cancer

W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition

W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.

Bladder Cancer

Toni K. Choueiri, MD, on Urothelial Cancer: Trial Results From Borealis-2

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on apatorsen plus docetaxel vs docetaxel alone in platinum-resistant metastatic urothelial cancer. (Abstract 289)

Bladder Cancer

Karim Chamie, MD, on Bladder Cancer: Optimizing Surgical and Medical Therapies

Karim Chamie, MD, of the University of California, Los Angeles, discusses induction and maintenance BCG therapy in non–muscle-invasive bladder cancer.

Kidney Cancer

Sumanta K. Pal, MD, on Advanced Renal Cancer: Treatment Challenges

Sumanta K. Pal, MD, of the City of Hope, summarizes a session he co-chaired on the opportunities and challenges in systemic therapy for advanced renal cancer, including imaging as a biomarker of response and optimal selection of front-line treatments. (General Session 9)

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: Active Surveillance

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he co-chaired, which included discussion of Canadian vs U.S. guidelines; ProtecT; genomic and hereditary tests; and imaging to guide active surveillance. (General Session 1)

Advertisement

Advertisement




Advertisement